Current Science

Open Access Open Access  Restricted Access Subscription Access

Bio-Business in Brief:The Case for Ambitious Action in the Public Sector


Affiliations
1 Department of Biotechnology, Government of India, Block 2, 7th Floor, CGO Complex, Lodi Road, New Delhi 110 003, India
2 Institute of Bioinformatics and Applied Biotechnology, Biotech Park, Electronics City Phase I, Bengaluru 560 100, India
 

At the time of independence, India was a poor country. Nevertheless, the Government saw fit to invest in industry and research. In recent decades the public sector has received a bad press, with pressure to reduce it while increasing the role of the private sector. The public sector is not intrinsically bad, but has often been misused. The ‘market’ and the ‘state’ each have a role in economic development. To ensure steady growth of the economy, the country must ensure universal healthcare, for which it needs an innovative homegrown industry and universal good education. This requires large public investment.

Keywords

Basic Research, Biotech Industry, Liberalization, Pharma Industry, Public Sector.
User
Notifications
Font Size

  • Khilnani, S., The Idea of India, Penguin Books India, New Delhi, 2004.

  • Srinivasan, R., Time for a ‘Right to Healthcare’. The Hindu, 18 December 2013.

  • Bhaduri, A. and Nayyar, D., The Intelligent Person’s Guide to Liberalization, Penguin Books, New Delhi, 1996.

  • Press, W. H., What’s so special about science (and how much should we spend on it?) Science, 2013, 342, 817–822.

  • Balaram, P., Requiem for a missing generation. Curr. Sci., 2002, 83, 1297–1298.

  • Ray, A. S. and Bhaduri, S., Competing through technological capacity. The Indian pharmaceutical industry in a changing global landscape. CSSP Electronic Working Paper Series, Paper no. 3, 2012.

  • Gehl Sampath, P., Indian pharma within global reach? United Nations University, Working paper series #2006-031, 2006.

  • Greene, W., The emergence of India’s pharmaceutical industry and implications for the US generic drug market. Office of Economics Working Paper Number 2007-05-A, US International Trade Commission, 2007.

  • Sengupta, A., Joseph, R. K., Modi, S. and Syam, N., Economic constraints to access to essential medicines in India. Society for Economic and Social Studies, New Delhi and the Centre for Technology and Development Studies in Collaboration with WHO Country Office for India, 2008.

  • Kamiike, A., Sato, T. and Aggarwal, A., Productivity dynamics in the Indian pharmaceutical industry: evidence from plant-level panel data. Sci. Technol. Soc., 2012, 17, 431–452.

  • Dikshit, M. and Dikshit, D. K., Drug discovery research in India. Curr. Sci., 2016, 111, 252–255.

  • Saberwal, G., India’s intellectual property-based biomedical startups. Curr. Sci., 2016, 110, 167–171.

  • Kessel, M., A lifeline for the biotech sector. Nature Biotechnol., 2009, 27, 123–124.

  • Sanyal, A., The curious case of the Bombay Plan. Contemp. Issues Ideas Soc. Sci., 2010, 6(1).

  • Parthasarathy, A., Acquisition and development of technology some issues. Econ. Polit. Wkly, 1987, 22, M131–M138.

  • Nayyar, D., Catch Up, Developing Countries in the World Economy, Oxford University Press, New York, 2013.

  • Bagla, P., India aims a probe at Mars – and at earthly prestige. Science, 2013, 341, 1328.

  • Tyabji, N., Gaining technical know-how in an unequal world. Penicillin manufacture in Nehru’s India. Technol. Cult., 2004, 45, 331–349.


Abstract Views: 266

PDF Views: 81




  • Bio-Business in Brief:The Case for Ambitious Action in the Public Sector

Abstract Views: 266  |  PDF Views: 81

Authors

K. Vijay Raghavan
Department of Biotechnology, Government of India, Block 2, 7th Floor, CGO Complex, Lodi Road, New Delhi 110 003, India
Gayatri Saberwal
Institute of Bioinformatics and Applied Biotechnology, Biotech Park, Electronics City Phase I, Bengaluru 560 100, India

Abstract


At the time of independence, India was a poor country. Nevertheless, the Government saw fit to invest in industry and research. In recent decades the public sector has received a bad press, with pressure to reduce it while increasing the role of the private sector. The public sector is not intrinsically bad, but has often been misused. The ‘market’ and the ‘state’ each have a role in economic development. To ensure steady growth of the economy, the country must ensure universal healthcare, for which it needs an innovative homegrown industry and universal good education. This requires large public investment.

Keywords


Basic Research, Biotech Industry, Liberalization, Pharma Industry, Public Sector.

References





DOI: https://doi.org/10.18520/cs%2Fv113%2Fi10%2F1841-1845